Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Hycamtin, Topotecan, Topotecan Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Topotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Cervical adenocarcinoma
  • Cervical cancer
  • Cervical carcinoma
  • Ovarian cancer
  • Ovarian neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Topotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase I Trial of Periocular Topotecan in Retinoblastoma

    NCT00460876 · start 2007-03

    Registered record
    Registry ID
    NCT00460876
    Conditions
    Retinoblastoma
    Interventions
    Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-04
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinoblastoma
    InterventionTopotecan
    PhasePhase 1
    Registry statusCompleted

  • Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

    NCT00638898 · start 2007-02-26

    Registered record
    Registry ID
    NCT00638898
    Conditions
    Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell T
    Interventions
    busulfan; melphalan; topotecan hydrochloride; laboratory biomarker analysis; filgrastim; autologous hematopoietic stem cell transplantation; pharmacological study; autologous bone marrow transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-02-26
    Completion
    2024-12-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor +20 more
    Interventionbusulfan; melphalan; topotecan hydrochloride; laboratory biomarker analysis +4 more
    PhasePhase 1
    Registry statusCompleted

  • Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

    NCT00379457 · start 2006-06

    Registered record
    Registry ID
    NCT00379457
    Conditions
    Sarcoma
    Interventions
    dactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; ifosfamide; topotecan hydrochloride; vincristine sulfate; vinorelbine tartrate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride +7 more
    PhasePhase 3
    Registry statusUnknown

  • Phase 1 Intrathecal Topotecan for Neoplastic Meningitis

    NCT00674674 · start 2005-10

    Registered record
    Registry ID
    NCT00674674
    Conditions
    Neoplastic Meningitis
    Interventions
    Topotecan; Topotecan; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10
    Completion
    2010-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplastic Meningitis
    InterventionTopotecan; Topotecan; Topotecan
    PhasePhase 1
    Registry statusCompleted

  • Topotecan for Irinotecan-Refractory SCLC

    NCT00502762 · start 2004-09

    Registered record
    Registry ID
    NCT00502762
    Conditions
    Lung Cancer; Refractory to Chemotherapy
    Interventions
    topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2004-09
    Completion
    2007-08
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Refractory to Chemotherapy
    Interventiontopotecan
    PhasePhase 2
    Registry statusUnknown

  • Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

    NCT00502892 · start 2004-08

    Registered record
    Registry ID
    NCT00502892
    Conditions
    Solid Tumors
    Interventions
    Topotecan; Ifosfamide; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08
    Completion
    2010-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionTopotecan; Ifosfamide; Carboplatin
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    NCT00057837 · start 2004-07-14

    Registered record
    Registry ID
    NCT00057837
    Conditions
    Extensive Stage Small Cell Lung Cancer
    Interventions
    G-CSF; Cisplatin; Etoposide; Irinotecan; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07-14
    Completion
    2012-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Small Cell Lung Cancer
    InterventionG-CSF; Cisplatin; Etoposide; Irinotecan +1 more
    PhasePhase 2
    Registry statusCompleted

  • Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

    NCT00610571 · start 2004-04

    Registered record
    Registry ID
    NCT00610571
    Conditions
    Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma
    Interventions
    Oral Topotecan and Temodar
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-04
    Completion
    2012-04
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Gliosarcoma; Anaplastic Astrocytoma
    InterventionOral Topotecan and Temodar
    PhasePhase 1
    Registry statusCompleted

  • Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

    NCT00308165 · start 2004-03

    Registered record
    Registry ID
    NCT00308165
    Conditions
    Brain Neoplasms, Primary Malignant
    Interventions
    Convection-Enhanced Delivery; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-03
    Completion
    2016-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Neoplasms, Primary Malignant
    InterventionConvection-Enhanced Delivery; Topotecan
    PhasePhase 1
    Registry statusCompleted

  • Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

    NCT00287963 · start 2004-02

    Registered record
    Registry ID
    NCT00287963
    Conditions
    Lung Cancer
    Interventions
    topotecan hydrochloride; vinorelbine tartrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-02
    Completion
    2010-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventiontopotecan hydrochloride; vinorelbine tartrate
    PhasePhase 1
    Registry statusCompleted

  • Weekly Topotecan Therapy in Patients With Ovarian Cancer

    NCT00194935 · start 2003-02

    Registered record
    Registry ID
    NCT00194935
    Conditions
    Ovarian Cancer
    Interventions
    Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-02
    Completion
    2006-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionTopotecan
    PhasePhase 2
    Registry statusTerminated

  • Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

    NCT00046800 · start 2002-09

    Registered record
    Registry ID
    NCT00046800
    Conditions
    Ovarian Neoplasms
    Interventions
    OSI-211 (Liposomal Lurtotecan)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2003-03
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Neoplasms
    InterventionOSI-211 (Liposomal Lurtotecan)
    PhasePhase 2
    Registry statusCompleted

  • Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

    NCT00053287 · start 2002-09

    Registered record
    Registry ID
    NCT00053287
    Conditions
    Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
    Interventions
    carboplatin; fludarabine phosphate; thalidomide; topotecan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2007-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
    Interventioncarboplatin; fludarabine phosphate; thalidomide; topotecan hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

    NCT00320983 · start 2002-03

    Registered record
    Registry ID
    NCT00320983
    Conditions
    Cervical Cancer
    Interventions
    Topotecan; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-03
    Completion
    2005-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Cancer
    InterventionTopotecan; Cisplatin
    PhasePhase 1
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

    NCT00003827 · start 1999-01

    Registered record
    Registry ID
    NCT00003827
    Conditions
    Leukemia; Myelodysplastic Syndromes
    Interventions
    amifostine trihydrate; cytarabine; topotecan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    1999-01
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Myelodysplastic Syndromes
    Interventionamifostine trihydrate; cytarabine; topotecan hydrochloride
    PhasePhase 2
    Registry statusUnknown